AbbVie: Phase 3 lymphoma data suggest improved treatment outcomes

AbbVie announced findings from an interim analysis of the Phase 3 iNNOVATE study evaluating IMBRUVICA plus RITUXAN in previously untreated and relapsed/refractory patients with Waldenstrom’s macroglobulinemia, a rare type of non-Hodgkin’s lymphoma. At a median follow up of 26.5 months, the study successfully met its primary endpoint, demonstrating a significant improvement in progression-free survival with ibrutinib plus rituximab compared to rituximab alone. Patients taking ibrutinib plus rituximab also experienced an 80 percent reduction in relative risk of disease progression or death than those only treated with rituximab. Additionally, the data found that the combination with ibrutinib provided reductions in infusion reactions associated with rituximab and immunoglobin M flare. “The iNNOVATE study provides further evidence of the potential clinical benefit of IMBRUVICA-based combination therapy in patients with Waldenstrom’s macroglobulinemia,” said Thorsten Graef, M.D., Ph.D., Head of Clinical Development at Pharmacyclics LLC, an AbbVie company. “The data from this chemotherapy-free combination regimen suggests that patients with Waldenstrom’s macroglobulinemia, including those who are newly diagnosed, could have another beneficial therapeutic option in the future.”

https://bit.ly/2syrOjo